Skip to main content
Assets
Abbott Laboratories logo
ABT.NYSE
Abbott Laboratories
Health Care · Health Care Equipment

Global healthcare company developing medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals.

HQ: United StatesListed: United States

Historical AI Forecasts

Audit every published iPulse AI forecast batch and immutable historical research document for Abbott Laboratories.

Historical AI Forecasts

Abbott Laboratories (ABT.NYSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 5 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 19 March 2026Deep analysis 19 March 2026

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
Warren Buffett AI advisor icon

Warren Buffett AI

The Value Seeker FrameworkAI Researcher

Model rating

Buy

5-Year Return Est.

+84.8%

Includes 1.69% annual net dividend contribution

1. Investment Thesis — Base Case

Abbott Laboratories presents a classic value ownership proposition: a wonderful business offered at a discounted price due to a solvable, temporary friction. The base case projects the core Medical Devices and Diabetes Care divisions to compound at low double digits. The Libre franchise will reliably exceed $10 billion in annual revenue, while the integration of Exact Sciences, though initially challenging, will ultimately yield a new pillar of structural growth in oncology diagnostics. The NEC litigation will inevitably result in a painful but financially manageable settlement, clearing the dark cloud currently suppressing the . Over the five-year horizon, will grow at roughly 8-10% annually.

  • FreeStyle Libre sustains global dominance, expanding further into Type 2 and wellness markets.
  • Volt PFA system gains meaningful share, stabilizing the Electrophysiology division.
  • NEC litigation results in a manageable multi-billion dollar settlement, paid over time.
  • Nutrition segment normalizes by late 2026 as pricing actions stick and WIC comps ease.
  • Strong permits aggressive debt paydown post-Exact Sciences acquisition.
  • The structurally re-rates upward as uncertainty dissipates, aligning price with .

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.74.05104.15134.24164.34194.43Mar 2021Sep 2023Mar 2026Sep 2028Mar 2031Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (USD)
Observed price2021-03-14118
Observed price2021-03-27121
Observed price2021-04-13123
Observed price2021-05-01120
Observed price2021-05-05119
Observed price2021-05-27116
Observed price2021-06-04109
Observed price2021-06-22111
Observed price2021-06-26114
Observed price2021-07-09119
Observed price2021-07-22120
Observed price2021-08-13123
Observed price2021-08-17124
Observed price2021-09-03129
Observed price2021-09-12127
Observed price2021-10-04116
Observed price2021-10-17117
Observed price2021-10-30129
Observed price2021-11-16130
Observed price2021-11-25125
Observed price2021-11-29126
Observed price2021-12-16136
Observed price2021-12-29141
Observed price2022-01-16129
Observed price2022-01-24121
Observed price2022-02-02130
Observed price2022-02-15124
Observed price2022-03-09117
Observed price2022-03-13117
Observed price2022-03-17122
Observed price2022-04-08123
Observed price2022-04-30114
Observed price2022-05-08108
Observed price2022-05-26115
Observed price2022-06-03116
Observed price2022-06-16103
Observed price2022-06-25107
Observed price2022-07-04110
Observed price2022-07-21108
Observed price2022-08-12111
Observed price2022-08-16111
Observed price2022-08-29102
Observed price2022-09-11107
Observed price2022-09-2897.3
Observed price2022-10-16104
Observed price2022-10-2096.2
Observed price2022-11-0296.7
Observed price2022-11-24106
Observed price2022-12-03106
Observed price2022-12-11110
Observed price2022-12-24108
Observed price2023-01-11114
Observed price2023-01-24112
Observed price2023-02-10108
Observed price2023-02-14107
Observed price2023-03-0899.3
Observed price2023-03-2598.2
Observed price2023-04-03102
Observed price2023-04-12103
Observed price2023-04-29111
Observed price2023-05-03112
Observed price2023-05-25103
Observed price2023-06-11101
Observed price2023-06-20106
Observed price2023-06-24108
Observed price2023-07-07107
Observed price2023-07-25114
Observed price2023-08-11105
Observed price2023-08-15105
Observed price2023-09-06101
Observed price2023-09-10102
Observed price2023-10-0296.0
Observed price2023-10-0696.2
Observed price2023-10-1592.2
Observed price2023-11-1094.6
Observed price2023-11-23103
Observed price2023-11-27102
Observed price2023-12-15109
Observed price2023-12-23109
Observed price2024-01-10114
Observed price2024-01-18114
Observed price2024-01-31113
Observed price2024-02-13113
Observed price2024-03-06120
Observed price2024-03-10120
Observed price2024-03-23112
Observed price2024-04-10112
Observed price2024-04-18106
Observed price2024-05-01106
Observed price2024-05-19104
Observed price2024-05-27102
Observed price2024-06-09106
Observed price2024-06-22105
Observed price2024-07-14103
Observed price2024-07-18101
Observed price2024-08-09109
Observed price2024-08-13109
Observed price2024-09-04115
Observed price2024-09-13117
Observed price2024-09-26113
Observed price2024-10-05113
Observed price2024-10-18117
Observed price2024-11-13116
Observed price2024-11-21118
Observed price2024-11-26119
Observed price2024-12-17113
Observed price2024-12-30113
Observed price2025-01-08114
Observed price2025-01-17114
Observed price2025-02-07132
Observed price2025-02-12132
Observed price2025-03-05137
Observed price2025-03-10133
Observed price2025-03-23126
Observed price2025-04-09125
Observed price2025-04-26130
Observed price2025-05-18135
Observed price2025-05-22132
Observed price2025-05-27132
Observed price2025-06-13135
Observed price2025-06-26137
Observed price2025-07-13132
Observed price2025-07-18122
Observed price2025-08-08132
Observed price2025-08-13131
Observed price2025-08-21132
Observed price2025-09-08132
Observed price2025-09-21135
Observed price2025-10-12133
Observed price2025-10-25126
Observed price2025-11-03124
Observed price2025-11-16130
Observed price2025-11-25128
Observed price2025-12-08123
Observed price2025-12-29124
Observed price2026-01-07127
Observed price2026-01-16123
Observed price2026-01-29106
Observed price2026-02-24114
Observed price2026-03-04111
Observed price2026-03-09111
Observed price2026-03-30103
Observed price2026-04-08103
Observed price2026-04-2192.1
Observed price2026-04-3090.6
Observed price2026-05-1384.1
Observed price2026-05-2685.9
Observed price2026-06-0891.2
Observed price2026-06-2190.0
Observed price2026-07-0495.5
Observed price2026-07-21100
Observed price2026-08-08108
Observed price2026-08-21117
Observed price2026-09-03109
Observed price2026-09-07106
Observed price2026-09-15102
Observed price2026-09-18103
Published advisor forecast2026-03-18108
Published advisor forecast2026-06-18112
Published advisor forecast2026-09-18114
Published advisor forecast2026-12-18119
Published advisor forecast2027-03-18124
Published advisor forecast2027-06-18132
Published advisor forecast2027-09-18136
Published advisor forecast2027-12-18139
Published advisor forecast2028-03-18144
Published advisor forecast2028-06-18147
Published advisor forecast2028-09-18151
Published advisor forecast2028-12-18154
Published advisor forecast2029-03-18159
Published advisor forecast2029-06-18162
Published advisor forecast2029-09-18159
Published advisor forecast2029-12-18164
Published advisor forecast2030-03-18170
Published advisor forecast2030-06-18174
Published advisor forecast2030-09-18176
Published advisor forecast2030-12-18179
Published advisor forecast2031-03-18184

2. Scenarios & Signals

Bull case

The Bull Case materializes if management ruthlessly resolves the legal overhang early and executes the Exact Sciences integration flawlessly. If Abbott negotiates an unexpectedly favorable NEC settlement and Libre 4 launches with non-invasive features, the expands exponentially.

  • NEC litigation settles for under $2 billion, preserving pristine options.
  • Exact Sciences captures dominant share in blood-based screening, validating the $21 billion premium.
  • The stock multiple immediately re-rates to 25x as the legal cloud evaporates.
  • accelerates past 12% annually, driving massive compound returns.

Bear case

The Bear Case unfolds if the NEC litigation spirals out of control and the Exact Sciences integration destroys owner value. If state courts consistently award nuclear verdicts and Cologuard faces lethal competition, the fundamental fortress cracks.

  • State courts award successive $500M+ verdicts, pushing total NEC liability past $15 billion.
  • FreeStyle Libre 3 recall issues persist, allowing Dexcom to permanently steal .
  • Exact Sciences faces margin collapse from cheap liquid biopsy competitors.
  • Debt burden threatens the credit rating, forcing a dividend freeze and permanent .

Current crowd narrative

The noisy market currently believes Abbott is ''. Sell-side research is paralyzed by the existential terror of the necrotizing enterocolitis (NEC) baby formula litigation, spooked by recent nuclear verdicts in state courts. Furthermore, the narrative fixates on the near-term debt burden of the $21B Exact Sciences acquisition and the stubborn volume declines in the Nutrition segment. The consensus trade is a cautious hold; the crowd treats the stock as a , anchoring entirely to the legal liabilities and completely ignoring the compounding cash flows of the underlying medical devices.

Alpha-gap assessment

The lies in the mathematical reality of Abbott's cash-generating power versus the perceived legal risk. The market treats the NEC litigation as an unquantifiable black swan, heavily suppressing the . However, Abbott generates over $11 billion in annually. Even a worst-case $5 billion to $8 billion legal settlement, amortized over several years, is easily absorbed without impairing the dividend, R&D, or debt service capability. Mr. Market is allowing a temporary, ring-fenceable legal friction to obscure a permanent, widening driven by FreeStyle Libre and structural heart devices.

Convergence catalyst

The announcement of a comprehensive, ring-fenced global settlement or a definitive string of defense victories in the NEC bellwether trials. Once the liability is mathematically capped, the uncertainty discount will vanish. This is anticipated to occur in late 2026 or 2027, forcing the market to rapidly reprice the asset based on its 10%+ .

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus